VivoSeq
Dermatology

Chronic Idiopathic Urticaria

21

Pipeline Programs↗

2

Active Trials↗

15

Companies Involved↗

Chronic Idiopathic Urticaria is an emerging landscape with 21 programs across 15 companies. The most active players are Glaxo Dba Glaxosmithkline, Novartis, AstraZeneca. 3 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

31/100

Completion Rate

83/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2I

Immunex

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2UCB logo

UCB

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

17 of 24 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody625%Protein / enzyme14%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed19 · 70%
Terminated4 · 15%
Unknown status2 · 7%
Not yet recruiting1 · 4%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Molecular Endotypes of Chronic Idiopathic Urticaria
Active, not recruiting·UUniversity of Colorado, Denver·Phase 4·NCT04774315·15 enrolled
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
Not yet recruiting·—·Phase 3·NCT07486583·40 enrolled
Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)
Completed·—·N/A·NCT00723736·100 enrolled
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Completed·UUniversity of Colorado, Denver·Phase 4·NCT01701583·10 enrolled
Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
Completed·JJohns Hopkins University·Phase 2·NCT02031679·38 enrolled
Methotrexate in the Treatment of Chronic Idiopathic Urticaria
Completed·UUniversity Hospital, Tours·Phase 3·NCT01960283·83 enrolled
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
Completed·—·Phase 4·NCT00536380·314 enrolled
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Completed·—·Phase 3·NCT00421109·522 enrolled
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed·—·N/A·NCT00724698·3,011 enrolled
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Completed·JJohns Hopkins University·Phase 4·NCT03111628·18 enrolled
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
Completed·UCB logoUCB·Phase 3·NCT00525382·134 enrolled
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
Completed·—·Phase 4·NCT00751218·174 enrolled
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Completed·Roche logoRoche·Phase 3·NCT01264939·336 enrolled
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Completed·Roche logoRoche·Phase 2·NCT00866788·90 enrolled
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
Completed·Roche logoRoche·Phase 4·NCT02392624·206 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)